FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1250-1252 March 24, 2005 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Reyes, F. PubMed Citation

It is well known that localized cancers, including aggressive non-Hodgkin's lymphoma, have a better prognosis than cancers that have spread. When the results of treatment for aggressive non-Hodgkin's lymphoma are reported, the results for Ann Arbor stage I disease (involvement of a single lymph-node region) are typically reported separately from those for stage III (involvement of lymph nodes on both sides of the diaphragm) and stage IV (stage III plus extranodal involvement). The results of treatment for stage II disease (involvement of two or more lymph nodes on the same side of the diaphragm) may be included in either group.

. . . [Full Text of this Article]

Source Information

From the University of Nebraska Medical Center, Omaha.

This article has been cited by other articles:

• Gemici, C., Salepci, T. (2007). How Can We Determine the Role of Radiotherapy in the Treatment of Localized Aggressive Non-Hodgkin's Lymphoma?. JCO 25: 2857-2857 [Full Text]